Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Dec 10, 2020 2:53pm
104 Views
Post# 32078530

RE:RE:RE:Update

RE:RE:RE:Update
Ryeman40 wrote: Somebody asked about corporate update on biopub at the end and Dan said somewhere middle of January.  I wonder if they'll have anything on possible meetings from JP Morgan conference. 


Ryeman ... if my notes are correct, someone asked about employees and any additional hirings.
I thought Dan said that they've done the hirings but that more information would be available with the corporate update by mid-January.  It almost made me think he'd be jockeying the board to create one more company position as he did in the past - but - that's just a guess.

Might have read that wrong ... but that's how it hit me.  Will need to listen to the recorded BioPUB when it's released.

I wouldn't expect anything from J.P.Morgan except a video/presentation if they are presenting.  If it's one-on-one meetings, we probably won't hear anything.

JMO.
<< Previous
Bullboard Posts
Next >>